Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization an – GlobeNewswire October 10, 2023
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial – AstraZeneca September 22, 2023
MDMA could be approved in the US in MONTHS: Rave drug ‘statistically significant’ in treating PTSD November 30, 2022November 30, 2022